AbCellera Biologics Inc. (ABCL) › Operating IncomeAbCellera Biologics Inc. (ABCL) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2019: -$4.12M2020: $156.03M2021: $204.41M2022: $216.51M2023: -$237.21M2024: -$314.77M2025: -$217.10M-$217.10M2019Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$217.10M+31.0%2024-$314.77M-32.7%2023-$237.21M-209.6%2022$216.51M+5.9%2021$204.41M+31.0%2020$156.03M+3889.9%2019-$4.12M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share